Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Selective estrogen receptor modulators enhance CNS remyelination independent of estrogen receptors.

Rankin KA, Mei F, Kim K, Shen YA, Mayoral SR, Desponts C, Lorrain DS, Green AJ, Baranzini SE, Chan JR, Bove R.

J Neurosci. 2019 Jan 29. pii: 1530-18. doi: 10.1523/JNEUROSCI.1530-18.2019. [Epub ahead of print]

PMID:
30696729
2.

Effect of pregnancy loss on MS disease activity.

Kaplan TB, Bove R, Galetta K, Healy B, Chitnis C, Houtchens M.

J Neurol Sci. 2019 Feb 15;397:58-60. doi: 10.1016/j.jns.2018.12.028. Epub 2018 Dec 21.

PMID:
30590343
3.

A Videogame-Based Digital Therapeutic to Improve Processing Speed in People with Multiple Sclerosis: A Feasibility Study.

Bove RM, Rush G, Zhao C, Rowles W, Garcha P, Morrissey J, Schembri A, Alailima T, Langdon D, Possin K, Gazzaley A, Feinstein A, Anguera J.

Neurol Ther. 2018 Nov 30. doi: 10.1007/s40120-018-0121-0. [Epub ahead of print]

PMID:
30506301
4.

A Parental Perspective on Strengthening Knowledge After Acute Flaccid Myelitis.

Bove R, Werdal H, Olivera E.

JAMA Pediatr. 2018 Nov 30. doi: 10.1001/jamapediatrics.2018.4893. [Epub ahead of print] No abstract available.

PMID:
30500055
5.

We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Commentary.

Bove R.

Mult Scler. 2018 Oct 22:1352458518808205. doi: 10.1177/1352458518808205. [Epub ahead of print] No abstract available.

PMID:
30346219
6.

Cognitive Deficits in Multiple Sclerosis: Recent Advances in Treatment and Neurorehabilitation.

Sokolov AA, Grivaz P, Bove R.

Curr Treat Options Neurol. 2018 Oct 22;20(12):53. doi: 10.1007/s11940-018-0538-x. Review.

PMID:
30345468
7.

Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.

Bove R, Bevan C, Crabtree E, Zhao C, Gomez R, Garcha P, Morrissey J, Dierkhising J, Green AJ, Hauser SL, Cree BA, Wallin MT, Gelfand JM.

Mult Scler. 2018 Aug 24:1352458518793527. doi: 10.1177/1352458518793527. [Epub ahead of print]

PMID:
30141729
8.

Reproductive period and epigenetic modifications of the oxidative phosphorylation pathway in the human prefrontal cortex.

Bove RM, Patrick E, Aubin CM, Srivastava G, Schneider JA, Bennett DA, De Jager PL, Chibnik LB.

PLoS One. 2018 Jul 27;13(7):e0199073. doi: 10.1371/journal.pone.0199073. eCollection 2018.

9.

A case for gender-based approach to multiple sclerosis therapeutics.

Houtchens MK, Bove R.

Front Neuroendocrinol. 2018 Jul;50:123-134. doi: 10.1016/j.yfrne.2018.07.001. Epub 2018 Jul 21. Review.

PMID:
30040969
10.

Caring for Women with Multiple Sclerosis Across the Lifespan.

Rankin K, Bove R.

Curr Neurol Neurosci Rep. 2018 May 23;18(7):36. doi: 10.1007/s11910-018-0846-2. Review.

PMID:
29789964
11.

Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD.

Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, Green AJ, Hauser SL, Bove R.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 19;5(3):e453. doi: 10.1212/NXI.0000000000000453. eCollection 2018 May.

12.

Why monkeys do not get multiple sclerosis (spontaneously): An evolutionary approach.

Bove RM.

Evol Med Public Health. 2018 Jan 23;2018(1):43-59. doi: 10.1093/emph/eoy002. eCollection 2018. Review.

13.

Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.

Bove R, Healy BC, Musallam A, Soltany P, Diaz-Cruz C, Sattarnezhad N, Glanz BI, Kivisäkk P, Miller KK, Chitnis T.

Mult Scler. 2018 Jan 1:1352458517750768. doi: 10.1177/1352458517750768. [Epub ahead of print]

PMID:
29320952
14.

Harnessing electronic medical records to advance research on multiple sclerosis.

Damotte V, Lizée A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, Gomez R, Lincoln R, Tang W, Chen T, Lee N, Villoslada P, Hollenbach JA, Bevan CD, Graves J, Bove R, Goodin DS, Green AJ, Baranzini SE, Cree BA, Henry RG, Hauser SL, Gelfand JM, Gourraud PA.

Mult Scler. 2018 Jan 1:1352458517747407. doi: 10.1177/1352458517747407. [Epub ahead of print]

PMID:
29310490
15.

Hormones and MS: Risk factors, biomarkers, and therapeutic targets.

Bove R, Gilmore W.

Mult Scler. 2018 Jan;24(1):17-21. doi: 10.1177/1352458517737396.

PMID:
29307303
16.

Diagnosing multiple sclerosis: art and science.

Bove RM, Hauser SL.

Lancet Neurol. 2018 Feb;17(2):109-111. doi: 10.1016/S1474-4422(17)30461-1. Epub 2017 Dec 21. No abstract available.

PMID:
29275980
17.

High risk of postpartum relapses in neuromyelitis optica spectrum disorder.

Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen F, Mealy MA, Sorum J, Mutch K, Tobyne SM, Ruprecht K, Buckle G, Levy M, Wingerchuk D, Paul F, Cross AH, Jacobs A, Chitnis T, Weinshenker B.

Neurology. 2017 Nov 28;89(22):2238-2244. doi: 10.1212/WNL.0000000000004681. Epub 2017 Nov 1.

18.

Remyelinating Pharmacotherapies in Multiple Sclerosis.

Bove RM, Green AJ.

Neurotherapeutics. 2017 Oct;14(4):894-904. doi: 10.1007/s13311-017-0577-0. Review.

19.

SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.

Bove R, Chitnis T, Cree BA, Tintoré M, Naegelin Y, Uitdehaag BM, Kappos L, Khoury SJ, Montalban X, Hauser SL, Weiner HL; SUMMIT Consortium.

Mult Scler. 2018 Oct;24(11):1485-1498. doi: 10.1177/1352458517726657. Epub 2017 Aug 29.

PMID:
28847219
20.

Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study.

Bove R, Elsone L, Alvarez E, Borisow N, Cortez MM, Mateen FJ, Mealy MA, Mutch K, Tobyne S, Ruprecht K, Buckle G, Levy M, Wingerchuk DM, Paul F, Cross AH, Weinshenker B, Jacob A, Klawiter EC, Chitnis T.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar 24;4(3):e339. doi: 10.1212/NXI.0000000000000339. eCollection 2017 May.

21.

Oral contraceptives and MS disease activity in a contemporary real-world cohort.

Bove R, Rankin K, Chua AS, Saraceno T, Sattarnezhad N, Greeke E, Stuart F, LaRussa A, Glanz BI, Chitnis T.

Mult Scler. 2018 Feb;24(2):227-230. doi: 10.1177/1352458517692420. Epub 2017 Feb 3.

PMID:
28155573
22.

Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.

Block VJ, Lizée A, Crabtree-Hartman E, Bevan CJ, Graves JS, Bove R, Green AJ, Nourbakhsh B, Tremblay M, Gourraud PA, Ng MY, Pletcher MJ, Olgin JE, Marcus GM, Allen DD, Cree BA, Gelfand JM.

J Neurol. 2017 Feb;264(2):316-326. doi: 10.1007/s00415-016-8334-6. Epub 2016 Nov 28.

23.

Immunology of neuromyelitis optica during pregnancy.

Davoudi V, Keyhanian K, Bove RM, Chitnis T.

Neurol Neuroimmunol Neuroinflamm. 2016 Oct 7;3(6):e288. eCollection 2016 Dec. Review.

24.

Patient Management Problem-Preferred Responses.

Bove R.

Continuum (Minneap Minn). 2016 Oct;22(5, Neuroimaging):1738-1746. No abstract available.

PMID:
27741002
25.

Patient Management Problem.

Bove R.

Continuum (Minneap Minn). 2016 Oct;22(5, Neuroimaging):1731-1737. No abstract available.

PMID:
27741001
26.

Women's experiences of menopause in an online MS cohort: A case series.

Bove R, Vaughan T, Chitnis T, Wicks P, De Jager PL.

Mult Scler Relat Disord. 2016 Sep;9:56-9. doi: 10.1016/j.msard.2016.06.015. Epub 2016 Jul 1.

27.

Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis.

Bove R, White CC, Fitzgerald KC, Chitnis T, Chibnik L, Ascherio A, Munger KL.

Neurology. 2016 Oct 4;87(14):1457-1463. Epub 2016 Sep 7.

28.

Complex relation of HLA-DRB1*1501, age at menarche, and age at multiple sclerosis onset.

Bove R, Chua AS, Xia Z, Chibnik L, De Jager PL, Chitnis T.

Neurol Genet. 2016 Jul 26;2(4):e88. doi: 10.1212/NXG.0000000000000088. eCollection 2016 Aug.

29.

Longitudinal BMI trajectories in multiple sclerosis: Sex differences in association with disease severity.

Bove R, Musallam A, Xia Z, Baruch N, Messina S, Healy BC, Chitnis T.

Mult Scler Relat Disord. 2016 Jul;8:136-40. doi: 10.1016/j.msard.2016.05.019. Epub 2016 May 31.

PMID:
27456889
30.

Women's Issues in Multiple Sclerosis.

Bove R.

Semin Neurol. 2016 Apr;36(2):154-62. doi: 10.1055/s-0036-1579736. Epub 2016 Apr 26. Review.

PMID:
27116722
31.

Adolescence, imperceptible boundary between normality and pathology: a literature review.

Bove D, Bove RM, Caccavale S, Bravaccio C, Marino M, La Montagna M.

Minerva Pediatr. 2016 Apr;68(2):148-51. Review.

PMID:
27002489
32.

Ataxia telangiectasia, Menkes kinky hair disease and neurocutaneous melanosis.

Caccavale S, Bove D, Bove RM, LA Montagna M.

G Ital Dermatol Venereol. 2017 Feb;152(1):58-65. doi: 10.23736/S0392-0488.16.05083-5. Epub 2016 Mar 22. Review.

PMID:
27002302
33.

Association between adiposity and cognitive function in young men: Hormonal mechanisms.

Bove RM, Gerweck AV, Mancuso SM, Bredella MA, Sherman JC, Miller KK.

Obesity (Silver Spring). 2016 Apr;24(4):954-61. doi: 10.1002/oby.21415. Epub 2016 Feb 16.

34.

Multiple sclerosis in men: management considerations.

Bove R, McHenry A, Hellwig K, Houtchens M, Razaz N, Smyth P, Tremlett H, Sadovnick AD, Rintell D.

J Neurol. 2016 Jul;263(7):1263-73. doi: 10.1007/s00415-015-8005-z. Epub 2016 Jan 2. Review.

PMID:
26725085
35.

Effect of growth hormone on cognitive function in young women with abdominal obesity.

Bove RM, White CC, Gerweck AV, Mancuso SM, Bredella MA, Sherman JC, Miller KK.

Clin Endocrinol (Oxf). 2016 Apr;84(4):635-7. doi: 10.1111/cen.12996. Epub 2016 Feb 2. No abstract available.

36.

Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis.

Bove R, White CC, Giovannoni G, Glanz B, Golubchikov V, Hujol J, Jennings C, Langdon D, Lee M, Legedza A, Paskavitz J, Prasad S, Richert J, Robbins A, Roberts S, Weiner H, Ramachandran R, Botfield M, De Jager PL.

Neurol Neuroimmunol Neuroinflamm. 2015 Oct 15;2(6):e162. doi: 10.1212/NXI.0000000000000162. eCollection 2015 Dec.

37.

Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort.

Bove R, Healy BC, Musallam A, Glanz BI, De Jager PL, Chitnis T.

Mult Scler. 2016 Jun;22(7):935-43. doi: 10.1177/1352458515606211. Epub 2015 Oct 7.

38.

The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS.

Bove R, Malik MT, Diaz-Cruz C, Chua A, Saraceno TJ, Bargiela D, Greeke E, Glanz BI, Healy BC, Chitnis T.

Neurology. 2015 Oct 6;85(14):1209-13. doi: 10.1212/WNL.0000000000001990. Epub 2015 Sep 4.

39.

Skin and brain: itch and psychiatric disorders.

Caccavale S, Bove D, Bove RM, LA Montagna M.

G Ital Dermatol Venereol. 2016 Oct;151(5):525-9. Epub 2015 Apr 9. Review.

PMID:
25854671
40.

Patients report worse MS symptoms after menopause: findings from an online cohort.

Bove R, Healy BC, Secor E, Vaughan T, Katic B, Chitnis T, Wicks P, De Jager PL.

Mult Scler Relat Disord. 2015 Jan;4(1):18-24. doi: 10.1016/j.msard.2014.11.009. Epub 2014 Dec 9.

PMID:
25787049
41.

Adolescence: psychopathological discomfort, distress or psychiatric disorder? Clinical experience, description and analysis of a sample.

Bove D, Bove RM, Caccavale S, Bravaccio C, LA Montagna M.

Minerva Pediatr. 2017 Apr;69(2):87-94. doi: 10.23736/S0026-4946.16.04228-6. Epub 2014 Dec 12.

PMID:
25502734
42.

Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review.

Bove R, Alwan S, Friedman JM, Hellwig K, Houtchens M, Koren G, Lu E, McElrath TF, Smyth P, Tremlett H, Sadovnick AD.

Obstet Gynecol. 2014 Dec;124(6):1157-68. doi: 10.1097/AOG.0000000000000541. Review.

PMID:
25415167
43.

An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2.

Bakshi R, Neema M, Tauhid S, Healy BC, Glanz BI, Kim G, Miller J, Berkowitz JL, Bove R, Houtchens MK, Severson C, Stankiewicz JM, Stazzone L, Chitnis T, Guttmann CR, Weiner HL, Ceccarelli A.

Neuroreport. 2014 Oct 1;25(14):1156-61. doi: 10.1097/WNR.0000000000000244.

44.

Low testosterone is associated with disability in men with multiple sclerosis.

Bove R, Musallam A, Healy BC, Raghavan K, Glanz BI, Bakshi R, Weiner H, De Jager PL, Miller KK, Chitnis T.

Mult Scler. 2014 Oct;20(12):1584-92. doi: 10.1177/1352458514527864. Epub 2014 Apr 7.

45.

The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis.

Bove R, Chitnis T.

Mult Scler. 2014 Apr;20(5):520-6. doi: 10.1177/1352458513519181. Epub 2014 Feb 21. Review.

PMID:
24561324
46.

Patient management problem.

Bove RM.

Continuum (Minneap Minn). 2014 Feb;20(1 Neurology of Pregnancy):230-4, 235-44. doi: 10.1212/01.CON.0000443852.01923.08. Review. No abstract available.

PMID:
24492825
47.

Neuroradiology in women of childbearing age.

Bove RM, Klein JP.

Continuum (Minneap Minn). 2014 Feb;20(1 Neurology of Pregnancy):23-41. doi: 10.1212/01.CON.0000443835.10508.2b. Review.

PMID:
24492809
48.

Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women.

Bove R, Secor E, Chibnik LB, Barnes LL, Schneider JA, Bennett DA, De Jager PL.

Neurology. 2014 Jan 21;82(3):222-9. doi: 10.1212/WNL.0000000000000033. Epub 2013 Dec 11.

49.

Modeling disease severity in multiple sclerosis using electronic health records.

Xia Z, Secor E, Chibnik LB, Bove RM, Cheng S, Chitnis T, Cagan A, Gainer VS, Chen PJ, Liao KP, Shaw SY, Ananthakrishnan AN, Szolovits P, Weiner HL, Karlson EW, Murphy SN, Savova GK, Cai T, Churchill SE, Plenge RM, Kohane IS, De Jager PL.

PLoS One. 2013 Nov 11;8(11):e78927. doi: 10.1371/journal.pone.0078927. eCollection 2013.

50.

Increased leptin and A-FABP levels in relapsing and progressive forms of MS.

Messina S, Vargas-Lowy D, Musallam A, Healy BC, Kivisakk P, Gandhi R, Bove R, Gholipour T, Khoury S, Weiner HL, Chitnis T.

BMC Neurol. 2013 Nov 11;13:172. doi: 10.1186/1471-2377-13-172.

Supplemental Content

Support Center